Stocks · News reference
UBS analyst Andrea Alfonso maintains Elanco Animal Health (NYSE:ELAN) with a Buy and raises the price target from $31 to $33.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Elanco Animal Health (NYSE:ELAN) held its second-quarter earnings conference call on Wednesday. Below is the complete transcript from the call. Benzinga APIs provide real-time access to earnings call transcripts and
Lawrence Erik Kurzius, Director at Elanco Animal Health, purchased 40,000 shares at $23.40 per share on August 20, 2026, expanding his direct holdings by 27%. The insider purchase signals confidence in the company, with analysts showing strong bullish sentiment—89% of 18 analysts rate it a buy with a median 12-month price target of $32, representing potential 31% upside.
The completed 25,000-square-foot Elwood site expansion bolsters Elanco's monoclonal antibody (mAb) production; supports delivery of next-generation pipelineINDIANAPOLIS, Aug. 26, 2026 /PRNewswire/ -- Elanco Animal
Bryn Talkington picked Horizon Kinetics, Stephanie Link chose Elanco Animal Health, and Jason Snipe recommended Netflix.